- Home
- SY vs MNPR Comparison
SY vs MNPR Comparison
Compare SY & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SY
- MNPR
- Stock Information
- Founded
- SY 2013
- MNPR 2014
- Country
- SY China
- MNPR United States
- Employees
- SY N/A
- MNPR N/A
- Industry
- SY EDP Services
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- SY Technology
- MNPR Health Care
- Exchange
- SY Nasdaq
- MNPR Nasdaq
- Market Cap
- SY 384.4M
- MNPR 390.5M
- IPO Year
- SY 2019
- MNPR 2019
- Fundamental
- Price
- SY $3.27
- MNPR $89.62
- Analyst Decision
- SY Strong Buy
- MNPR Strong Buy
- Analyst Count
- SY 1
- MNPR 12
- Target Price
- SY $5.50
- MNPR $96.64
- AVG Volume (30 Days)
- SY 829.2K
- MNPR 89.6K
- Earning Date
- SY 11-19-2025
- MNPR 11-07-2025
- Dividend Yield
- SY 0.80%
- MNPR N/A
- EPS Growth
- SY N/A
- MNPR N/A
- EPS
- SY N/A
- MNPR N/A
- Revenue
- SY $197,807,588.00
- MNPR N/A
- Revenue This Year
- SY $8.61
- MNPR N/A
- Revenue Next Year
- SY $54.55
- MNPR N/A
- P/E Ratio
- SY N/A
- MNPR N/A
- Revenue Growth
- SY N/A
- MNPR N/A
- 52 Week Low
- SY $0.66
- MNPR $4.50
- 52 Week High
- SY $6.28
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- SY 35.37
- MNPR 59.62
- Support Level
- SY $3.33
- MNPR $86.26
- Resistance Level
- SY $3.46
- MNPR $104.00
- Average True Range (ATR)
- SY 0.21
- MNPR 8.69
- MACD
- SY -0.06
- MNPR -1.59
- Stochastic Oscillator
- SY 6.50
- MNPR 52.81
About SY So-Young International Inc. American Depository Shares
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.